J&J will announce a huge Buyout on GERON sooner than later...
Racist Steve Bannon has resigned from the Trump team in disgrace. Stock market reacts positively. Now we just need the orange clown to quit and America will be great again.
new patent ( 1 of 177 ) United States Patent 9,732,114 Gryaznov , et al. August 15, 2017 Compounds having anti-adhesive effects on cancer cells
Abstract Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3'.fwdarw.P5' thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.
Inventors: Gryaznov; Sergei M. (San Mateo, CA), Shay; Jerry W. (Dallas, TX), Wright; Woodring (Arlington, TX) Applicant: Name City State Country Type
Gryaznov; Sergei M. Shay; Jerry W. Wright; Woodring San Mateo Dallas Arlington CA TX TX US US US Assignee: GERON CORPORATION (Menlo Park, CA) BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX) Family ID: 1000002778857 Appl. No.: 14/336,443 Filed: July 21, 2014 Prior Publication Data
Trump never would have gotten elected if the politicians had not failed this country so miserably the last many years. That is how Trump got elected and that is where the real blame lies is on our career politicians that look after themselves and their gold-plated retirements and a gold-plated Healthcare.
W/ the 20/80 split on retail sales of IMET, I cannot imagine that JnJ would offer a buy out. They already have the golden goose locked up and will so for years. Opting in will cost 35M, a milestone payment, offering a buy out would cost 1/2 a billion at least. Where's the financial logic? Down the road, if the "billion dollar block buster" forecast by JnJ for IMET holds true, the 20%....200M a year is a large chunk of change and with those kinds of earnings would easily get the stock into the double digits. But buyout?
STAY STRONG BOSTON ! REJECT RACISM IN ALL ITS FORMS ! Especially the Republican Party which endorses racism and hate with their leader Donald Trump. There is NO DOUBT that Donald Trump is an overt racist. 1) The Founder of Birtherism (yet Obama was proven to be a natural born citizen) 2) Settled with the Justice Department over housing discrimination and denying blacks rental units 3) Equating neo-Nazis and white supremacists as "many fine people" 4) Considering pardoning convicted racist sheriff Joe Arpaio 5)Trump on eugenics, "if you put together the genes of a superior woman and a superior man, you get a superior offspring" 6) Trump on himself, "not all people are created equal. I have the winning gene." 7) Launched his campaign by calling Mexicans rapists. 8) Threatening to going to war with the parents of a Muslim soldier killed in battle 9) Encouraged violence against minority protesters at his rally, 10) Promising to build a wall and make Mexico pay for it. This man built his presidential campaign on racial resentment and fear. REJECT. RESIST. IMPEACH AND REPLACE. DELETE HATE.. AND MAKE AMERICA GREAT AGAIN.
A bunch of sniffing Trump haters on this MB.
Opt-in or Buy Out you gotta be in it to win it!!! Dragging us through the mud won't last forever!!!
Myelodysplastic Syndrome (MDS Last Updated August 16, 2017
Recruiting 86 sites
Seems like Janssen is waiting for the FDA go ahead.
Study to Evaluate Imetelstat (JNJ-63935937) in Subjects with International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Global Trial Finder
The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA)
They're reporting at ASH, we already know what they're going to say. Their drug works better than what's out there. It even works better for people as a front line drug for MDS and MF! And it cures cancer for some with MF. Buying. Buying a lot. I'm going to turn every $1 I put into GERN into $50.
BUY BUY BUY BUY BUY!!!!!
Let's see how hard black works today on a $2. stock.
Several have asked how do investors make chippy accountable.
But, with few viable choices considering the current state of GERN affairs!
The Board of Directors is supposed to protect investors interests from bad/ poor management. They are supposed to be the "checks and balances" in the corporate world.
Thus far, the GERN BOD hasn't done much or anything.
Want an example?
Just look at chippy's compensation plan that is void of almost everything financial like income, revenue, fees, profit and PPS performance. They set the bar so low like attending conferences, etc. Come on now, attending conferences for a performance metric, that's RIDICULOUS!!!
So, start communicating with the BOD. Flood them with comments. Demand that they do their job!
See where this leads, and, try something else if it doesn't work.
Have a better idea?
Let's hear it.
Of course, IMO.
Shorts need to buy up 33 million GERN shares and Johnson and Johnson just called GERN'S drug 1 of Johnson and Johnson's top 6 future money makers.
repost from seeking alpha
black, How you doing on holding chippy and co. accountable? I mean really, you been singing that tune for years and I have to ask "how's that work'n for you?"
Left wing radicals want to takes down the socialist drain. Why? Why do they hate America. This is the progressive agenda. Destroy America. Venezuela here we come. The left wing dems will kill the golden goose. California wants to leave. Adios. Perhaps they should rejoin Mexico; as CA was part of the territory we stole from them in 1850. Hasta la vista,
Here's a little taste of what this poster named Paul is all about..Guess what he is? It looks like wayne has more relatives than we knew about.
Paul11 hours ago Geron Corporation A BUNCH OF SNIFFING TRUMP HATERS ON THIS MB.
Paul10 days ago ***TRUMP IS RIGHT.*** Mitch is impotent.
Paul4 days agoReplied to a reaction Johnson & Johnson Wrong, it's out of control Political Correctness that is the problem. ***THE PRESIDENT DID NOTHING WRONG.***
Paul14 days ago Minnesota mosque explosion 'deeper and scarier' than threats HOW DO WE KNOW THE MUSLIMS DIDN'T DO THIS?
Paul14 days ago Minnesota mosque explosion 'deeper and scarier' than threats They better be scared....MOST OF US DON'T WANT THAT TERRORIST RELIGION HERE. Mark Dayton sounded like a sniffing apologist.
Paul 22 days ago Trump just endorsed police violence and people are horrified Get over it SNOWFLAKES, this country has been way too soft on criminals. Its about time we crack down.
Paul 24 days ago Scaramucci on White House leakers: 'I'm going to fire everybody' ***I think Tony is going to do a GOOD job.***
from seeking alpha -- new patent listed on fresh patents
Title: Guanine analogs as telomerase substrates and telomere length affectors. Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases. ...
Guanine Analogs As Telomerase Substrates And Telomere Length Affectors
This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds a
Analyst PIPER JAFFRAY and STIFEL NICOLAUS both have strong buy ratings on GERN.
Despite all the noise generated on this message board, these Mayo results are why I am still invested in Geron.
Bone marrow fibrosis was reversed in ALL 4 patients who had a complete response, and a molecular response occurred in 3 of the 4 patients. Response rates were (_27%_) among patients with a JAK2 mutation versus 0% among those without a JAK2 mutation (P=0.30) and (_32%_) among patients without an ASXL1 mutation versus 0% among those with an ASXL1 mutation (P=0.07). The rate of complete response was (_38%_) among patients with a mutation in SF3B1 or U2AF1 versus 4% among patients without a mutation in these genes.
These results had Never happened with any drug therapy prior to Imetelstat.